Table 3.

Agents in preclinical development

Name/ development partners	Type/target	Activity spectrum	Other characteristics	Vision for development
MMV 253 (previously AZ13721412)/MMV and Zydus Cadila [142]	Triaminopyrimidine, Plasmodium ATPase inhibitor	Blood schizonticide	Long acting	Part of a single-dose radical cure
AN 13762/MMV, University of California, San Francisco [143]	Benzoxaborole, mechanism of action unknown	Blood schizonticide	Reassuring pre-clinical toxicology	Part of a single-dose radical cure, prevention
JPC-3210/MMV and Zydus Cadila [90]	Aminomethylphenol	Blood schizonticide	Long acting	Treatment and prevention
UCT 943 (previously MMV 642943)/MMV, H3D, University of Cape Town	PfPI(4)K inhibitor [144]	Multi-stage, falciparum and vivax	–	Back-up for MMV048 [71] (part of a single-dose radical cure, transmission blocking, prevention)
NPC1161B/University of Mississippi [93, 145]	8-Aminoquinoline (single enantiomer)	Multi-stage	Superior radical curative activity to primaquine in animal models [146]	Vivax malaria relapse prevention
SC83288/University of Heidelberg [92]	Amicarbalide derivative	Blood schizonticide	Rapid action (log parasite reduction ratio ~ 3 in a mouse model)	Severe malaria treatment
SAR121 (previously MMV688533)/Sanofi, MMV	Unknown mechanism of action	Blood schizonticide	Long acting	Part of a single-dose radical cure
DM1157(PL 69)/DesignMedix	“Reversed chloroquine”, similar mechanism of action	Blood schizonticide	No published data (similar to chloroquine)	Part of a single-dose radical cure [147]